Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463775 | 1.00 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL60399 | 1.00 | — | — | |
| SCHEMBL2638 | 1.00 | — | — | |
| SCHEMBL1521924 | 1.00 | — | — | |
| SCHEMBL20055722 | 1.00 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL10546260 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL5881106 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL6053445 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL16492 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL18507037 | 0.96 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2TSHRKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | claimed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | claimed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | claimed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | claimed |
| EP-0476515-A1 | New amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | claimed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| JP-8283244-A | — | — | None | — | — | JP | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| WO-2024071216-A1 | PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-23 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| WO-1995000537-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0476515-A1 | New amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-4374129-A | Antibiotically active aminopapulacandin derivatives | CIBA-GEIGY CORPORATION (US) | 1983-02-15 | — | — | US | disclosed |
| EP-0054514-A1 | Derivatives of aminopapulacandin having antibiotic activity | CIBA-GEIGY AG (CH) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | HSD17B10 2077/4885SMN1; SMN2 2791/4885ALDH1A1 1030/4885 |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | HSD17B10 2077/4885SMN1; SMN2 2791/4885ALDH1A1 1030/4885 |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | HSD17B10 2080/4885SMN1; SMN2 2727/4885ALDH1A1 977/4885 |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | HSD17B10 2080/4885SMN1; SMN2 2727/4885ALDH1A1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.